News
A study led by Bellvitge opens up a new option for the most difficult-to-treat migraine cases
About 30% of patients in whom preventive treatments had failed halved migraine days
Cancer also knows how to wait: an IDIBELL study uncovers the hidden step between a cancer-driving mutation and tumor biomass appearance
A mutation alone is not enough: tumour growth only begins when the environment provides the right conditions
Therapeutic virus combined with immunotherapy shows promising results in advanced head and neck cancer
The integration between care and research drives the development of new therapeutic options like this for patients with few alternatives.
Bellvitge identifies a genetic alteration that helps prevent complications of Rendu-Osler disease
The finding makes it possible to identify relatives who may have inherited the disease and to detect complications early
An innovative cell model allows progress in the research of a rare disease
A combination of drugs with potential for the treatment of tumours that appear in patients has been already dentified
“Thanks to REMMA Bellvitge, I can contribute to ALS research” (Valentín Urbina, ALS patient)
His participation in research helps advance knowledge about this rare disease
Bellvitge moves towards a more personalized ALS thanks to new biomarkers and digital technologies
Two studies with the participation of HUB and IDIBELL make it possible to better predict the evolution of the disease and open the door to precision medicine
IDIBELL and the EKHO Research Group of the University of Barcelona create “HÉLIX”, a pioneering project for the sonification of genomic data presented at the Sónar+D 2026 festival
The HÉLIX project connects science and art to translate the complexity of the genome into new sound languages
Epidemiologic data-driven model could help advance pancreatic cancer detection
The big challenge with pancreatic cancer is that it’s often caught too late